Review Article UPDATE ON MYASTHENIA GRAVIS: UPDATE ON MYASTHENIA GRAVIS

RAKESH K SINGH; VIKRAM  AGLAVE

doi:10.15713/ins.bhj.76

Authors

RAKESH K SINGH HON ASST PROF, DEPARTMENT OF NEUROLOGY, SIR J J HOSPITAL, GRANT MEDICAL COLLEGE, BYCULLA, MUMBAI, MAHARASTRA
Dr VIKRAM AGLAVE LECTURER, DEPARTMENT OF NEUROLOGY, SIR J J HOSPITAL, GRANT MEDICAL COLLEGE, BYCULLA, MUMBAI.

DOI:

https://doi.org/10.15713/ins.bhj.76

Keywords:

Myasthenia gravis. Thymus. Autoantibodies. Treatment guidelines

Abstract

Abstract

Myasthenia gravis is an autoimmune disease mediated by autoantibodies against various transmembrane proteins located on the post synaptic membrane. Our understanding of pathophysiology has vastly improved over the last decade, resulting in the development of individualized therapeutic options. Classification into myasthenia subgroups, depending on the antibody profile, helps to better characterize, treat, and prognosticate patients. It is quite evident that MuSK myasthenia needs early Rituximab intervention for a stable remission. Role of thymectomy, although never in doubt, was recently proven in randomized controlled trial. With the advent of monoclonal antibodies and other newer modalities, we should evolve beyond the conventional immunosuppressives, given their toxicities. Better potential options are now available to treat the refractory subgroup. Future of myasthenia treatment clearly has rosy predictions. Present review is an update on myasthenia gravis.

Author Biography

Dr VIKRAM AGLAVE , LECTURER, DEPARTMENT OF NEUROLOGY, SIR J J HOSPITAL, GRANT MEDICAL COLLEGE, BYCULLA, MUMBAI.

LECTURER, DEPARTMENT OF NEUROLOGY, SIR J J HOSPITAL, GRANT MEDICAL COLLEGE, BYCULLA, MUMBAI.

References

Gilhus NE. Myasthenia gravis. N. Engl. J. Med 2016 ; 375 :2570–2581.

Nico Melzer, Tobias Ruck, Peter Fuhr, Ralf Gold, Reinhard Hohlfeld, Alexander Marx, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis : a supplement to the Guidelines of the German Neurological Society. J Neurol 2016 ; 263 :1473–1494.

Breiner A, Widdifield J, Katzberg HD, Barnett C, Bril V, Tu K. Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscul Disord. 2016 Jan ;26(1) :41-6.

Andersen JB, Heldal AT, Engeland A, Gilhus NE. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta Neurol. Scand. 2014;129: 26–31.

Evoli A, Alboini PE, Damato V, Iorio R, Provenzano C, Bartoccioni E, et al. Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci. 2018 Jan ;1412(1) :82-89.

Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015; 14:1023–1036.

Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002;2(10):797–804.

Berrih-Aknin S, Le Panse R. Myasthenia gravis : a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun. 2014 Aug ;52 :90-100.

Cron MA, Maillard S, Villegas J, Truffault F, Sudres M, Dragin N, et al. Thymus involvement in early-onset myasthenia gravis. Ann N Y Acad Sci. 2018 Jan ;1412(1):137-145.

Luo J, Taylor P, Losen M, de Baets MH, Shelton GD, Lindstrom J. Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity. J Neurosci. 2009 Nov 4 ;29(44) :13898-908.

Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S. Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016 May ;12(5) :259-68.

Daroff RB, Jankovic J, Mazziotta JC, Scott L, editors. Bradley’s Neurology in Clinical Practice. London, New York, Oxford, Philadephia, St. Louis, Sydney, Toronto: Elsevier; 2016. ISBN: 978-0-323-28783-8. Pomeroy Seventh Edition.

Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008 Feb ;37(2) :141-9.

Evoli A, Alboini PE, Iorio R, Damato V, Bartoccioni E. Pattern of ocular involvement in myasthenia gravis with MuSK antibodies. J Neurol Neurosurg Psychiatry. 2017 ; 88 :761–3.

Rodolico C, Bonanno C, Toscano A, Vita G. MuSK-Associated Myasthenia Gravis : Clinical Features and Management. Front Neurol. 2020 ;11 :660.

Rubin DI, Litchy WJ. Severe, focal tibialis anterior and triceps brachii weakness in myasthenia gravis: a case report. J Clin Neuromuscul Dis 2011;12(4):219–222.

Trouth AJ, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis : A review. Autoimmune Disease. 2012 ;2012 :874680.

Nair AG, Patil-Chhablani P, Venkatramani DV, Gandhi RA. Ocular myasthenia gravis : a review. Indian J Ophthalmol. 2014 ;62(10) :985-991.

Van Stavern GP, Bhatt A, Haviland J, Black EH. A prospective study assessing the utility of Cogan’s lid twitch sign in patients with isolated unilateral or bilateral ptosis. J. Neurol. Sci. 2007 ; 256 ; 84–85.

Chatzistefanou KI, Kouris T, Iliakis E, Piaditis G, Tagaris G, Katsikeris N, et al. The ice pack test in the differential diagnosis of myasthenic diplopia. Ophthalmology. 2009 Nov ;116(11) :2236-43.

Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000 Jul 12 ;55(1) :16-23.

Gilhus, NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JGM, et al. Myasthenia gravis. Nat Rev Dis Primers 2019 ;5 :30.

Lazaridis K, Tzartos SJ. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Front. Immunol. 2020; 11:212.

Ali HB, Salort-Campana E, Grapperon AM, Gallard J, Franques J, Sevy, A, et al. New strategy for improving the diagnostic sensitivity of repetitive nerve stimulation in myasthenia gravis. Muscle Nerve 2017; 55: 532–538.

Pascuzzi RM. The edrophonium test. Seminars in Neurology 2003; 23:83–88.

Cortés-Vicente E, Gallardo E, Martínez MÁ, et al. Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin. JAMA Neurol. 2016 ;73(9) :1099–1104.

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy : American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10 ;36(17) :1714-1768.

Sanders DB, Wolfe GI, Benatar M, Evoli A, Nils E. Gilhus NE, Illa I, et al. international consensus guidance for management of myasthenia gravis. Executive summary. Neurology Jul 2016, 87 (4) 419-425.

Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, et al. European Federation of Neurological S. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17:893–902.

Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity 2010; 43, 428–435.

Khadilkar SV, Chaudhari CR, Patil TR, Desai ND, Jagiasi KA, Bhutada AG. Once myasthenic, always myasthenic? observations on the behavior and prognosis of myasthenia gravis in a cohort of 100 patients. Neurol India. 2014; Sep-Oct;62(5):492-7.

Narayanaswami P, Sanders DB, Wolfe GI, Benatar M, Evoli A, Cea G, et al. International Consensus Guidance for Management of Myasthenia Gravis 2020 Update. Neurology 2021; 96:114-122.

Al-Haidar M, Benatar M, Kaminski HJ. Ocular myasthenia. Neurol Clin. 2018; 36:241–51.

Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D. The association of British neurologists’ myasthenia gravis guidelines. Ann NY Acad Sci.2018; 1412:166–9.

McQuillen MP, Leone MG. A treatment carol: thymectomy revisited. Neurology. 1977 Dec;27(12):1103-6.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med. 2016 Aug 11;375(6):511-22.

Wendell LC, Levine JM. Myasthenic Crisis. The Neurohospitalist. 2011;1(1):16-22.

Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Therapeutic Advances in Neurological Disorders. January 2018.

Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med. 2013;86(2):255-260.

Tandan, R, Hehir MK, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve 56, 185–196 (2017).

Di Stefano V, Lupica A, Rispoli MG, Di Muzio A, Brighina F, Rodolico C. Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry. 2020 Apr;91(4):392-395.

Howard JF. Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo controlled, multicentre study. Lancet Neurol.2017; 16: 976–986.

Gable KL, Guptill JT. Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis. Front Immunol. 2020 Jan 10; 10:3052.

Bourque PR, Pringle CE, Cameron W, Cowan J, Chardon JW. Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study. PLoS One. 2016;11(8): e0159993.

Norwood F, Dhanjal M, Hill M, James N, Jungbluth H, Kyle P, et al. Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group. J Neurol Neurosurg Psychiatry. 2014 May;85(5):538-43.